Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
IRCCS Burlo Garofolo University of Trieste II Pathology Department, Brescia City Hospital, Italy, Department of Medical Sciences, University of Eastern Piedmont, Novara, Italy |
---|---|
Information provided by: | IRCCS Burlo Garofolo |
ClinicalTrials.gov Identifier: | NCT00677495 |
Undetected or untreated CD may cause severe complications later in life, such as autoimmune disorders.
It is recommended for subjects with autoimmune diseases or at risk for CD to be screened for CD and to repeat serological screening about every three years to detect cases of clinically silent, late-onset CD.
Celiac disease (CD) auto-antibodies against tissue transglutaminase (anti-tTG) are produced in the intestinal mucosa even when not measurable in serum. By using the phage display libraries technique it is possible to investigate in vivo (intestinal biopsy) early antibody responses in autoimmune disease. In particularly, this technique demonstrated that the humoral response against tissue transglutaminase occurs at the intestinal mucosal level, and that the human VH5 gene is the commonly used variable region by the celiac patients to build the anti-tTG. The intestinal mucosa production of IgA anti-tTG could be important in the diagnostic work-up of early-stage CD, when mucosal histology is not yet diagnostic.
We propose to first degree relatives of CD patients and to subjects with autoimmune disease a prospective study to uncover early-stage of gluten intolerance by measuring the mucosal VH5 restricted gene family anti-tTG clones in two biopsies: before and after one year of gluten free-diet (GFD).
Aims of this clinical trial are:
Condition | Intervention |
---|---|
Gluten-Genetic Predisposition Celiac Disease |
Dietary Supplement: Gluten-free diet |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Single Group Assignment |
Official Title: | Usefulness of Gluten-Free Diet in Gluten-Genetically Predisposed Subjects Positive to Intestinal-Mucosa Anti-Transglutaminase Antibodies |
Estimated Enrollment: | 27 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | May 2008 |
Estimated Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Italy, Friuli Venezia Giulia | |
IRCCS Burlo Garofolo | |
Trieste, Friuli Venezia Giulia, Italy, 34137 |
Principal Investigator: | Fabiana Ziberna | IRCCS Burlo Garofolo, Trieste, Italy |
Principal Investigator: | Serena Vatta | IRCCS Burlo Garofolo, Trieste, Italy |
Principal Investigator: | Stefano Martelossi, MD | IRCCS Burlo Garofolo, Trieste, Italy |
Principal Investigator: | Roberto Marzari | University of Trieste |
Principal Investigator: | Fiorella Florian | University of Trieste |
Principal Investigator: | Vincenzo Villanacci, MD | II Pathology Department, Brescia City Hospital, Italy, |
Principal Investigator: | Daniele Sblattero | Department of Medical Sciences, University of Eastern Pidmont, Novara, Italy |
Study Chair: | Alessandro Ventura, MD | IRCCS Burlo Garofolo, Trieste, Italy |
Study Director: | Tarcisio Not, MD | IRCCS Burlo Garofolo, Trieste, Italy |
Responsible Party: | IRCCS Burlo Garofolo ( Tarcisio Not, MD ) |
Study ID Numbers: | RC 25/07 |
Study First Received: | May 12, 2008 |
Last Updated: | September 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00677495 |
Health Authority: | Italy: Ministry of Health |
Gluten-free diet Celiac Disease Gluten-genetic predisposition Phage display library Autoimmune diseases |
Antibodies Metabolic Diseases Digestive System Diseases Autoimmune Diseases Disease Susceptibility Gastrointestinal Diseases |
Malabsorption Syndromes Celiac Disease Genetic Predisposition to Disease Metabolic disorder Intestinal Diseases Immunoglobulins |
Disease Attributes Pathologic Processes |